Vitamin D oily capsules — Competitive Intelligence Brief

Vitamin D oily capsules (Vitamin D oily capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D analog. Area: Osteoporosis, Rickets.

phase 3 Vitamin D analog Vitamin D receptor Osteoporosis, Rickets Small molecule

Target snapshot

Vitamin D oily capsules (Vitamin D oily capsules) — University Hospital, Basel, Switzerland. Vitamin D capsules work by regulating calcium levels in the body.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vitamin D oily capsules TARGET	Vitamin D oily capsules	University Hospital, Basel, Switzerland	phase 3	Vitamin D analog	Vitamin D receptor
Vitamin D (Cholecalciferol )	Vitamin D (Cholecalciferol )	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Vitamin/Steroid hormone	Vitamin D receptor (VDR)
Vitamin D3 tablets	Vitamin D3 tablets	Ain Shams University	marketed	Vitamin D supplement / Secosteroid	Vitamin D receptor (VDR)
Vitamin D3 as "BABY D3"	Vitamin D3 as "BABY D3"	Rambam Health Care Campus	marketed	Vitamin/Nutritional supplement	Vitamin D receptor (VDR)
doxercalciferol capsules, Hectorol® capsules	doxercalciferol capsules, Hectorol® capsules	Genzyme, a Sanofi Company	marketed	Vitamin D analog	Vitamin D receptor (VDR)
Ergocalciferol 50000 UNT	Ergocalciferol 50000 UNT	University of Alabama at Birmingham	marketed	Vitamin D supplement	Vitamin D receptor (VDR)
Vitamin D: solid form, start weekly	Vitamin D: solid form, start weekly	University Hospital, Basel, Switzerland	marketed	Vitamin/Steroid hormone	Vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin D analog class)

1. LEO Pharma · 2 drugs in this class
2. Genzyme, a Sanofi Company · 2 drugs in this class
3. National Cancer Institute, Naples · 2 drugs in this class
4. OPKO Health, Inc. · 2 drugs in this class
5. Joslin Diabetes Center · 1 drug in this class
6. Kyowa Kirin, Inc. · 1 drug in this class
7. Maimónides Biomedical Research Institute of Córdoba · 1 drug in this class
8. Shanghai Jiao Tong University Affiliated Sixth People's Hospital · 1 drug in this class
9. Shiraz University of Medical Sciences · 1 drug in this class
10. St. Justine's Hospital · 1 drug in this class